Clinical trial NCT00678392: Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Official title: AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Kidney Neoplasms
Keywords: Axitinib in Second Line Treatment of Patients With Metastatic Renal Cell Cancer
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-05-15
Enrollment: 723
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis
* Evidence of measurable disease
* Must have failed one prior systemic first-line regimen for metastatic renal cell cancer

Exclusion Criteria:

* Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy
* Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug

Primary outcomes:
measure: Progression-Free Survival (PFS)
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Objective Response Rate (ORR)
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Duration of Response (DR)
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Percentage of Participants With Adverse Events (AEs) by Severity
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Percentage of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Number of Participants With Clinically Significant Laboratory Abnormalities: Hematology
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Number of Participants With Clinically Significant Laboratory Abnormalities: Biochemistry
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Number of Participants With Clinically Significant Laboratory Abnormalities: Urinalysis
timeFrame: From initiation of treatment up to follow-up period (up to 3 years)
measure: Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score
timeFrame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
measure: Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Score
timeFrame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
measure: Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Health State Profile Utility Score
timeFrame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
measure: Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Visual Analog Scale (VAS)
timeFrame: Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698)
Other outcomes:
Locations:
city: Burbank
country: United States
facility: East Valley Hematology and Oncology Medical Group
state: California
city: Burbank
country: United States
facility: Maurice Berkowtiz, MD
state: California
city: Downey
country: United States
facility: Agajanian Institute of Oncology and Hematology
state: California
city: Glendale
country: United States
facility: Los Angeles Hematology/Oncology Medical Group
state: California
city: Los Angeles
country: United States
facility: Los Angeles Hematology/Oncology Medical Group
state: California
city: Los Angeles
country: United States
facility: LAC-USC Medical Center
state: California
city: Los Angeles
country: United States
facility: USC Norris Cancer Hospital and Clinics
state: California
city: Los Angeles
country: United States
facility: Kenmar Research Institute
state: California
city: Los Angeles
country: United States
facility: Metropolitan Hematology/Oncology Medical Group
state: California
city: Los Angeles
country: United States
facility: Ronald Regan UCLA Medical Center
state: California
city: Los Angeles
country: United States
facility: UCLA
state: California
city: Montebello
country: United States
facility: Agajanian Institute of Oncology and Hematology
state: California
city: West Covina
country: United States
facility: Brian LeBerthon, MD, A Medical Corporation
state: California
city: Whittier
country: United States
facility: Agajanian Institute of Oncology and Hematology
state: California
city: Aurora
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Aurora
country: United States
facility: University of Colorado Cancer Center
state: Colorado
city: Aurora
country: United States
facility: University of Colorado Denver: Division of Medical Oncology
state: Colorado
city: Boulder
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Colorado Springs
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Denver
country: United States
facility: Rocky Mountain Cancer Centers, LLP
state: Colorado
city: Denver
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Lakewood
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Littleton
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Lone Tree
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Longmont
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Parker
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Thornton
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Washington
country: United States
facility: Georgetown University Hospital, Lombardi Cancer Center
state: District of Columbia
city: Washington
country: United States
facility: Georgetown University Medical Center
state: District of Columbia
city: Bonita Springs
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Bradenton
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Cape Coral
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Cape Coral
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Deerfield Beach
country: United States
facility: University of Miami Sylvester at Deerfield Beach
state: Florida
city: Englewood
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Miami
country: United States
facility: University of Miami Hospital and Clinics
state: Florida
city: Naples
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Naples
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Orlando
country: United States
facility: M.D. Anderson Cancer Center Orlando
state: Florida
city: Orlando
country: United States
facility: Orlando Regional Medical Center
state: Florida
city: Port Charlotte
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Sarasota
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Sarasota
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Venice
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Venice
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Atlanta
country: United States
facility: Peachtree Hematology-Oncology Consultants, P.C.
state: Georgia
city: Ringgold
country: United States
facility: Chattanooga Oncology and Hematology Associates, PC
state: Georgia
city: Boise
country: United States
facility: Mountain States Tumor Institute
state: Idaho
city: Fruitland
country: United States
facility: Mountain States Tumor Institute
state: Idaho
city: Meridian
country: United States
facility: Mountain States Tumor Institute
state: Idaho
city: Nampa
country: United States
facility: Mountain States Tumor Institute
state: Idaho
city: Twin Falls
country: United States
facility: Mountain States Tumor Institute
state: Idaho
city: Maywood
country: United States
facility: Loyola University Chicago Cardinal Bernardin Cancer Center
state: Illinois
city: Carmel
country: United States
facility: Cental Indiana Cancer Centers
state: Indiana
city: Fishers
country: United States
facility: Central Indiana Cancer Centers
state: Indiana
city: Greenfield
country: United States
facility: Cental Indiana Cancer Centers
state: Indiana
city: Indianapolis
country: United States
facility: Central Indiana Cancer Centers
state: Indiana
city: Indianapolis
country: United States
facility: Central Indiana Cancer Centers
state: Indiana
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan Health System
state: Michigan
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Farmington Hills
country: United States
facility: Weisberg Cancer Treatment Center
state: Michigan
city: Minneapolis
country: United States
facility: University of Minnesota Medical Center Fairview
state: Minnesota
city: Columbia
country: United States
facility: Missouri Cancer Associates
state: Missouri
city: Saint Louis
country: United States
facility: St. John's Mercy Medical Center
state: Missouri
city: Saint Louis
country: United States
facility: St. John's Mercy, David C. Pratt Cancer Center
state: Missouri
city: Washington
country: United States
facility: St. John's Mercy Medical Center
state: Missouri
city: Henderson
country: United States
facility: Comprehensive Cancer Centers of Nevada
state: Nevada
city: Las Vegas
country: United States
facility: Comprehensive Cancer Centers of Nevada
state: Nevada
city: Las Vegas
country: United States
facility: Nevada Cancer Institute
state: Nevada
city: Las Vegas
country: United States
facility: Comprehensive Cancer Centers of Nevada
state: Nevada
city: Las Vegas
country: United States
facility: Comprehensive Cancer Centers of Nevada
state: Nevada
city: Hackensack
country: United States
facility: Hackensack University Medical Center
state: New Jersey
city: Hackensack
country: United States
facility: The Cancer Center at Hackensack University Medical Center - The Hillcrest Building
state: New Jersey
city: Hackensack
country: United States
facility: The Cancer Center at Hackensack University Medical Center
state: New Jersey
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Oneida
country: United States
facility: Department of Medicine MSG @ SUNY HSC @ Syrcacuse, Inc.
state: New York
city: Oswego
country: United States
facility: Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc.
state: New York
city: Syracuse
country: United States
facility: Suny Upstate Medical University
state: New York
city: Syracuse
country: United States
facility: Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc
state: New York
city: Cary
country: United States
facility: Raleigh Hematology Oncology Associates, DBA
state: North Carolina
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Durham
country: United States
facility: Investigational Chemotherapy Services
state: North Carolina
city: Elizabeth City
country: United States
facility: Albermarie Hospitals
state: North Carolina
city: Elizabeth City
country: United States
facility: Virginia Oncology Associates
state: North Carolina
city: Raleigh
country: United States
facility: Raleigh Hematology Oncology Associates, P.C.
state: North Carolina
city: Cleveland
country: United States
facility: Case Western Reserve University
state: Ohio
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
city: Columbus
country: United States
facility: Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
state: Ohio
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Columbus
country: United States
facility: James Care in Kenny
state: Ohio
city: Mayfield Heights
country: United States
facility: Monarch
state: Ohio
city: Mentor
country: United States
facility: Lake University - Ireland Cancer Center (LUICC)
state: Ohio
city: Orange Village
country: United States
facility: UHHS - Chagrin Highlands
state: Ohio
city: Westlake
country: United States
facility: UHHS - Westlake
state: Ohio
city: Eugene
country: United States
facility: Oncology Associates of Oregon, P.C.
state: Oregon
city: Springfield
country: United States
facility: Willamette Valley Cancer Institute and Research Center
state: Oregon
city: Hershey
country: United States
facility: Penn State Milton S. Hershey Medical Center
state: Pennsylvania
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
city: Easley
country: United States
facility: Cancer Centers of the Carolinas
state: South Carolina
city: Greenville
country: United States
facility: Cancer Centers of the Carolinas
state: South Carolina
city: Greenville
country: United States
facility: Hematology and Oncology Associates of SC, LLC - Eastside Medical Center
state: South Carolina
city: Seneca
country: United States
facility: Cancer Centers of the Carolinas, Seneca
state: South Carolina
city: Spartanburg
country: United States
facility: Cancer Centers of the Carolinas
state: South Carolina
city: Chattanooga
country: United States
facility: Chattanooga Oncology and Hematology Associates, PC
state: Tennessee
city: Chattanooga
country: United States
facility: Chattanooga Oncology Hematology Associates P.C.
state: Tennessee
city: Franklin
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Franklin
country: United States
facility: Vanderbilt-Ingram Cancer Center-Cool Springs
state: Tennessee
city: Gallatin
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Hermitage
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Hixson
country: United States
facility: Chattanooga Oncology & Hematology Associates
state: Tennessee
city: Lebanon
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Murfreesboro
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt-Ingram Cancer Center
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
city: Smyrna
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Austin
country: United States
facility: Texas Oncology - Austin Midtown
state: Texas
city: Austin
country: United States
facility: Texas Oncology - Central Midtown
state: Texas
city: Austin
country: United States
facility: Texas Oncology - Austin Central
state: Texas
city: Austin
country: United States
facility: Texas Oncology - South Austin
state: Texas
city: Austin
country: United States
facility: Texas Oncolgoy - Austin North
state: Texas
city: Austin
country: United States
facility: Texas Oncology - Austin Northwest
state: Texas
city: Bedford
country: United States
facility: Texas Oncology, P.A.
state: Texas
city: Cedar Park
country: United States
facility: Texas Oncology - Cedar Park
state: Texas
city: Dallas
country: United States
facility: Texas Oncology - Baylor Charles A. Sammons Cancer Center
state: Texas
city: Fort Worth
country: United States
facility: Investigation Products Center (IPC)
state: Texas
city: Fort Worth
country: United States
facility: Investigational Products Center (IPC)
state: Texas
city: Fort Worth
country: United States
facility: US Oncology Research and Clinical Pharmacy
state: Texas
city: Houston
country: United States
facility: Genitourinary Cancer Center
state: Texas
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
city: Round Rock
country: United States
facility: Texas Oncology - Seton Williamson
state: Texas
city: Round Rock
country: United States
facility: Texas Oncology - Round Rock
state: Texas
city: Tyler
country: United States
facility: Texas Oncology, P.A.
state: Texas
city: Webster
country: United States
facility: Deke Slayton Cancer Center
state: Texas
city: Webster
country: United States
facility: Texas Oncology - Clear Lake
state: Texas
city: Arlington
country: United States
facility: Virginia Cancer Specialists, PC
state: Virginia
city: Chesapeake
country: United States
facility: Virginia Oncology Associates
state: Virginia
city: Fairfax
country: United States
facility: Virginia Cancer Specialists, PC
state: Virginia
city: Gainesville
country: United States
facility: Virginia Cancer Specialists, PC
state: Virginia
city: Hampton
country: United States
facility: Virginia Oncology Associates
state: Virginia
city: Leesburg
country: United States
facility: Virginia Cancer Specialists, PC
state: Virginia
city: Newport News
country: United States
facility: Virginia Oncology Associates
state: Virginia
city: Norfolk
country: United States
facility: Virginia Oncology Associates
state: Virginia
city: Virginia Beach
country: United States
facility: Virginia Oncology Associates
state: Virginia
city: Woodbridge
country: United States
facility: Virginia Cancer Specialists, PC
state: Virginia
city: Seattle
country: United States
facility: Virginia Mason Medical Center, Section of Hematology/Oncology
state: Washington
city: Seattle
country: United States
facility: Seattle Cancer Care Alliance
state: Washington
city: Seattle
country: United States
facility: University of Washington Medical Center
state: Washington
city: Garran
country: Australia
facility: The Canberra Hospital, Medical Oncology
state: Australian Capital Territory
city: Kurralta Park
country: Australia
facility: Ashford Cancer Centre Research
state: South Australia
city: Ballarat
country: Australia
facility: Ballarat Oncology & Haematology Services
state: Victoria
city: East Melbourne
country: Australia
facility: Peter MacCallum Cancer Centre
state: Victoria
city: Heidelberg West
country: Australia
facility: Heidelberg Repatriation Hospital, Austin Health
state: Victoria
city: Heidelberg
country: Australia
facility: Austin Hospital, Austin Health
state: Victoria
city: Wien
country: Austria
facility: Med. Abt. KH Barmherzige Brueder Wien, Krankenhaus der Barmherzigen Brueder Wien
city: Wien
country: Austria
facility: Universitaets-Klinik fuer Innere Medizin I
city: Rio de Janeiro
country: Brazil
facility: Clinica Oncologistas Associados
state: RJ
city: Porto Alegre
country: Brazil
facility: Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita
state: RS
city: Barretos
country: Brazil
facility: Fundacao Pio XII Hospital de Cancer de Barretos
state: SP
city: Sao Paulo
country: Brazil
facility: Fundacao Antonio Prudente
state: SP
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
city: Edmonton
country: Canada
facility: Cross Cancer Institute
state: Alberta
city: Kelowna
country: Canada
facility: British Columbia Cancer Agency - Cancer Centre for the Southern Interior
state: British Columbia
city: Moncton
country: Canada
facility: Dr. Leon Richard Oncology Centre
state: New Brunswick
city: St. John's
country: Canada
facility: Dr. H. Bliss Murphy Cancer Centre
state: Newfoundland and Labrador
city: Oshawa
country: Canada
facility: RSM Durham Regional Cancer Centre Lakeridge Health Oshawa
state: Ontario
city: Beijing
country: China
facility: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
state: Chaoyang District
city: Nanjing
country: China
facility: The Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital
state: Jiangsu
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: P.R.
city: Xi'an
country: China
facility: Xijing Hospital, The Fourth Military Medical University
state: Shaanxi
city: Guangzhou
country: China
facility: Sun Yet-Sen University Cancer Center
city: Shanghai
country: China
facility: Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine
city: Tianjin
country: China
facility: Tianjin Oncology Hospital,biology treatment department
city: Lyon
country: France
facility: Centre Leon Berard
state: Cedex 08
city: Bordeaux Cedex
country: France
facility: Hopital Saint-André
city: CRETEIL Cedex
country: France
facility: Hôpital Henri Mondor
city: Marseille Cedex 09
country: France
facility: Institut Paoli-Calmettes
city: Paris Cedex 15
country: France
facility: Hopital Europeen Georges Pompidou
city: Rennes
country: France
facility: Centre Eugene Marquis
city: St Herblain Cedex
country: France
facility: Centre Rene Gauducheau - Service Oncologie Medicale
city: Tours Cedex 1
country: France
facility: CHRU de Tours - Hopital Bretonneau
city: Vandoeuvre les Nancy
country: France
facility: Centre Alexis Vautrin
city: Villejuif Cedex
country: France
facility: Institut Gustave Roussy / Service d'Immunotherapie
city: Aachen
country: Germany
facility: RWTH Aachen, Urologische Klinik
city: Berlin
country: Germany
facility: Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin
city: Essen
country: Germany
facility: Innere Klinik und Poliklinik fuer Tumorforschung, Universitaetsklinikum Essen
city: Hannover
country: Germany
facility: Klinikum Region Hannover Krankenhaus Siloah
city: Mainz
country: Germany
facility: Klinikum der Johannes-Gutenberg-Universitaet, III. Medizinische Klinik und Poliklinik
city: Muenchen
country: Germany
facility: Ludwig-Maximilians-Universitaet Muenchen, Klinikum Grosshadern Urologische Klinik und Poliklinik
city: Oldenburg
country: Germany
facility: Klinikum Oldenburg gGmbH, Klinik fuer Innere Medizin II Onkologie / Haematologie
city: Athens
country: Greece
facility: Alexandra University Hospital / Oncology Dept.
state: Attiki
city: Thessaloniki
country: Greece
facility: "Theagenio"Cancer Hospital / 3rd. Dept. of Clinical Oncology
state: Macedonia
city: Gurgaon
country: India
facility: Fortis Memorial Research Institute
state: Haryana
city: Kochi
country: India
facility: Amrita Institute of Medical Sciences
state: Kerala
city: Mumbai
country: India
facility: Dept. of Medical Oncology, Tata Memorial Hospital
state: Maharashtra
city: Ludhiana
country: India
facility: Christian Medical College & Hospital
state: Punjab
city: Jaipur
country: India
facility: Bhagwan Mahaveer Cancer Hospital and Research Center
state: Rajasthan
city: Dublin 24
country: Ireland
facility: Oncology Department
city: Arezzo
country: Italy
facility: UOC Oncologia Medica, Ospedale San Donato
city: Aviano (PN)
country: Italy
facility: Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS
city: Aviano (PN)
country: Italy
facility: Dipartimento dei laboratori diagnositici e per le terapie cellulari
city: Brescia
country: Italy
facility: Azienda Ospedaliera Spedali Civili di Brescia, Unita' Operativa Oncologia Medica
city: Cremona
country: Italy
facility: Struttura Complessa di Oncologia
city: Genova
country: Italy
facility: UOC Oncologia Medica B, IRCCS AO Universitaria San Martino
city: Milano
country: Italy
facility: Fondazione IRCCS, Istituto Nazionale dei Tumori, SC Oncologia Medica 2
city: Napoli
country: Italy
facility: Divisione di Oncologia, AORN Antonio Cardarelli
city: Napoli
country: Italy
facility: Istituto per lo Studio e la Cura dei Tumori Fondazione Pascale
city: Padova
country: Italy
facility: Unita' Operativa Oncologia Medica 2, Regione del Veneto
city: Pavia
country: Italy
facility: IRCCS Policlinico San Matteo
city: Roma
country: Italy
facility: Struttura Complessa di Oncologia Medica A
city: Roma
country: Italy
facility: Azienda Ospedaliera San Camillo Forlanini, Oncologia Medica, Padiglione Flajani, I piano
city: Rozzano (MI)
country: Italy
facility: UO di Oncologia ed Ematologia, Istituto Clinico Humanitas
city: Sapporo-shi
country: Japan
facility: Sapporo Medical University School of Medicine
state: Hokkaido
city: Sapporo
country: Japan
facility: Hokkaido University Hospital
state: Hokkaido
city: Tsukuba
country: Japan
facility: University of Tsukuba, Graduate School of Comprehensive Human Sciences, Department of Urology
state: Ibaraki
city: Osakasayama
country: Japan
facility: Kinki University Hospital
state: Osaka
city: Hamamatsu-City
country: Japan
facility: Hamamatsu University School of Medicine
state: Shizuoka
city: Sunto-gun
country: Japan
facility: Shizuoka Cancer Center
state: Shizuoka
city: Arakawa-ku
country: Japan
facility: Tokyo Women's Medical University Medical Center East, Department of Urology
state: Tokyo
city: Chuo-Ku
country: Japan
facility: National Cancer Center Hospital
state: Tokyo
city: Itabashi-ku
country: Japan
facility: Nihon University Itabashi Hospital
state: Tokyo
city: Shinjuku-ku
country: Japan
facility: Keio University Hospital
state: Tokyo
city: Shinjuku-ku
country: Japan
facility: Tokyo Women's Medical University Hospital
state: Tokyo
city: Ube-shi
country: Japan
facility: Yamaguchi University Hospital
state: Yamaguchi
city: Akita
country: Japan
facility: Akita University Hospital
city: Chiba
country: Japan
facility: Chiba Cancer Center
city: Fukuoka
country: Japan
facility: Kyushu University Hospital
city: Kumamoto
country: Japan
facility: Kumamoto University Hospital
city: Tokushima
country: Japan
facility: Tokushima University
city: Yamagata
country: Japan
facility: Yamagata University Hospital
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center, Urologic Oncology Clinic, Center for Specific Organs Cancer
state: Gyeonggi-do
city: Busan
country: Korea, Republic of
facility: Dong-A University Medical Center, Department of Medicine, Division of Hemato-Oncology
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Catholic University of Korea, Seoul St. Mary's Hospital, Department of Oncology
city: Poznan
country: Poland
facility: Centrum Medyczne HCP
state: Wielkopolska
city: Poznan
country: Poland
facility: Wielkopolskie Centrum Onkologii im.Marii Sklodowskiej-Curie
state: Wielkopolska
city: Gdansk
country: Poland
facility: Wojewodzkie Centrum Onkologii
city: Poznan
country: Poland
facility: Klinika Onkologii, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego
city: Poznan
country: Poland
facility: Pracownia Tomografii Komputerowej
city: Warszawa
country: Poland
facility: Klinika Onkologii, Wojskowy Instytut Medyczny
city: Wroclaw
country: Poland
facility: Klinika Urologii i Onkologii Urologicznej
city: Obninsk
country: Russian Federation
facility: Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia
state: Kaluga Region
city: Moscow
country: Russian Federation
facility: Cancer Research Center named after N.N. Blokhin, Biotherapy Department
city: Moscow
country: Russian Federation
facility: Cancer Research Center named after N.N.Blokhin, Chemotherapy Department
city: Moscow
country: Russian Federation
facility: Russian Research Center of Roentgenology and Radiology
city: Moscow
country: Russian Federation
facility: The Main Clinical Hospital of the Ministry of Internal Affairs of Russian Federation
city: Moscow
country: Russian Federation
facility: Moscow Research Institute of Oncology P.A. Herzen
city: St. Petersburg
country: Russian Federation
facility: City Clinical Oncology Dispensary
city: Singapore
country: Singapore
facility: National Cancer Centre Singapore
city: Bratislava
country: Slovakia
facility: Onkologicky Ustav sv. Alzbety
city: Bratislava
country: Slovakia
facility: Narodny Onkologicky ustav
city: Zilina
country: Slovakia
facility: Nemocnica s poliklinikou Zilina
city: L'hospitalet de Llobregat
country: Spain
facility: Institut Catala D'Oncologia L'Hospitalet
state: Barcelona
city: Pamplona
country: Spain
facility: Clinica Universitaria de Navarra
state: Navarra
city: Pamplona
country: Spain
facility: Hospital de Navarra
state: Navarra
city: Barcelona
country: Spain
facility: Hospital Vall D¿Hebron
city: Madrid
country: Spain
facility: Hospital Universitario Ramon Y Cajal
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Malaga
country: Spain
facility: Hospital Clinico Universitario Virgen de La Victoria
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet
city: Linkoping
country: Sweden
facility: Universitetssjukhuset, Onkologiska kliniken
city: Umea
country: Sweden
facility: Norrlands Universitetssjukhus, Onkologkliniken
city: Vaxjo
country: Sweden
facility: Onkologkliniken
city: Kaohsiung Hsien
country: Taiwan
facility: Chang Gung Medical Foundation-Kaohsiung Branch
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital, Department of Surgery
city: Taipei
country: Taiwan
facility: Department of Oncology, National Taiwan University Hospital
city: Taoyuan
country: Taiwan
facility: Chang Gung Medical Foundation-Linkou Branch
city: London
country: United Kingdom
facility: Royal Marsden Hospital
state: England
city: Northwood
country: United Kingdom
facility: Mount Vernon Cancer Centre
state: Middlesex
city: Bebington, Wirral
country: United Kingdom
facility: Clatterbridge Centre for Oncology NHS Foundation Trust
city: Birmingham
country: United Kingdom
facility: University of Birmingham, CRUK Institute for Cancer Studies
city: Bournemouth
country: United Kingdom
facility: Royal Bournemouth & Poole Hospitals
city: Bristol
country: United Kingdom
facility: Bristol Haematology and Oncology Centre
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital
city: Glasgow
country: United Kingdom
facility: The Beatson West of Scotland Cancer Centre
city: London
country: United Kingdom
facility: Department of Medical Oncology, St. Bartholomew's Hospital
city: Oxford
country: United Kingdom
facility: University Department of Medical Oncology/Oxford Cancer Centre
city: Surrey
country: United Kingdom
facility: Royal Marsden Hospital NHS Foundation Trust
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Murphy DA, Rini BI, Escudier B, Motzer RJ, Wang P, Li S, Williams JA, Tarazi JC, Martini JF. Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. Future Oncol. 2020 Jun;16(17):1199-1210. doi: 10.2217/fon-2020-0212. Epub 2020 May 4.
citation: Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial. Clin Genitourin Cancer. 2019 Jun;17(3):e689-e703. doi: 10.1016/j.clgc.2019.03.017. Epub 2019 Apr 1.
citation: de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
citation: Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.
citation: Grunwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May;67(5):952-8. doi: 10.1016/j.eururo.2014.12.036. Epub 2015 Jan 7.
citation: Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13.
citation: Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, Tarazi J, Chen C, Kim S, Ozono S, Naito S, Akaza H. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol. 2013 Jun;43(6):616-28. doi: 10.1093/jjco/hyt054. Epub 2013 Apr 28.
citation: Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16.
citation: Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J, Rosbrook B, Kim S, Motzer R. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer. 2013 Apr 30;108(8):1571-8. doi: 10.1038/bjc.2013.145. Epub 2013 Apr 11.
citation: Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4.